Stryker Corporation $SYK Stock Holdings Lowered by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. lowered its stake in Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 12,547 shares of the medical technology company’s stock after selling 275 shares during the period. J.W. Cole Advisors Inc.’s holdings in Stryker were worth $4,964,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. FourThought Financial Partners LLC grew its stake in Stryker by 15.3% during the 2nd quarter. FourThought Financial Partners LLC now owns 1,274 shares of the medical technology company’s stock valued at $504,000 after acquiring an additional 169 shares in the last quarter. Associated Banc Corp grew its holdings in Stryker by 3.7% during the second quarter. Associated Banc Corp now owns 23,088 shares of the medical technology company’s stock valued at $9,134,000 after purchasing an additional 826 shares during the last quarter. Columbia Bank lifted its stake in shares of Stryker by 3.0% in the second quarter. Columbia Bank now owns 5,987 shares of the medical technology company’s stock worth $2,332,000 after buying an additional 177 shares during the last quarter. Laurel Wealth Advisors LLC raised its holdings in Stryker by 39,309.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 59,902 shares of the medical technology company’s stock worth $23,699,000 after acquiring an additional 59,750 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Stryker by 23.5% during the second quarter. Steward Partners Investment Advisory LLC now owns 32,863 shares of the medical technology company’s stock valued at $13,002,000 after acquiring an additional 6,264 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Barclays lifted their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Truist Financial upped their price objective on shares of Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research report on Friday, November 14th. UBS Group set a $408.00 target price on shares of Stryker in a research note on Monday, October 13th. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $434.37.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. 5.90% of the stock is currently owned by company insiders.

Stryker Price Performance

Shares of Stryker stock opened at $372.04 on Thursday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The firm’s 50-day moving average price is $369.13 and its two-hundred day moving average price is $380.49. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $142.28 billion, a price-to-earnings ratio of 49.28, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.